Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Sub-Cellular Biochemistry|August 30, 2008
Fatty acid synthase activity in tumor cellsJoy L Little, Steven J KridelMolecular Cancer Therapeutics|December 17, 2008
Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell deathJoy L Little, Frances B Wheeler, Constantinos Koumenis, et al.Cancer Research|February 7, 2007
Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cellsJoy L Little, Frances B Wheeler, Diane R Fels, et al.Expert Opinion on Investigational Drugs|November 1, 2007
Fatty acid synthase inhibitors: new directions for oncologySteven J Kridel, W Todd Lowther, Charles W PembleCurrent Pharmaceutical Biotechnology|April 20, 2013
The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in TumorsLaura M Deford-Watts, Akiva Mintz, Steven J KridelCancer Research|March 18, 2004
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activitySteven J Kridel, Fumiko Axelrod, Natasha Rozenkrantz, et al.Cellular and Molecular Life Sciences : CMLS|November 26, 2009
CAS proteins in normal and pathological cell growth controlNadezhda Tikhmyanova, Joy L Little, Erica A GolemisJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2008
1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancerAmy L Vāvere, Steven J Kridel, Frances B Wheeler, et al.Cancer Metastasis Reviews|October 22, 2011
Polyunsaturated fatty acid metabolism in prostate cancerIsabelle M Berquin, Iris J Edwards, Steven J Kridel, et al.Nature Structural & Molecular Biology|July 10, 2007
Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by OrlistatCharles W Pemble, Lynnette C Johnson, Steven J Kridel, et al.Pageof 4